GoDubai
  
  
  
  
Citylife > Press Release
  Home Contact us Add to Favourites
Most Recent Postings
More Press Releses
Featured Sections

Event Finder
A daily roundup of exhibitions, promotions and other events in Dubai and the rest of the Emirates.
Submit an Event
Latest Dubai Press Releases >>

 
  Share
  • The pharmaceutical leader conducted an industry-first head-to-head study of two biologic therapies commonly used to treat the illness: vedolizumab and adalimumab
  • Vedolizumab was found to be superior in achieving clinical remission and mucosal healing at week 52
  • Study focused on patients with moderately to severely active ulcerative colitis  
Dubai, UAE, March 11, 2019:   Global biopharmaceutical company Takeda today announced the results of its pioneering VARSITY study into the effectiveness of two common therapies used to treat Ulcerative Colitis. Shared at the 14th Congress of the European Crohn's and Colitis Organization (ECCO) in Copenhagen Denmark, the findings showed that the use of vedolizumab – a gut-selective biologic treatment, was more effective overall at tackling the illness when compared to adalimumab– a common anti-tumor therapy.
 
Specifically, the study found that by week 52 of treatment among patients with moderate to severely active ulcerative colitis, 31.3 percent of those receiving vedolizumab intravenously experienced clinical remission*, compared to 22.5 percent of patients receiving adalimumab via injection at week 52. In addition, 39.7 percent of patients treated with vedolizumab recorded mucosal healing** - a slowing of the disease's progression, compared to 27.7 percent of those receiving adalimumab.
 
A non-statistically significant difference in favor of adalimumab was seen among patients who stopped taking oral corticosteroids - steroid hormones that are usually produced in the adrenal gland and were in clinical remission*** at week 52. Meanwhile, although the study was not conducted to compare the safety of the two treatments, patients treated with vedolizumab had a lower rate (62.7 percent) of adverse effects over 52 weeks compared to patients receiving adalimumab treatment (69.2 percent). Those treated with vedolizumab recorded a lower rate of infection (33.5 percent) compared to patients treated with adalimumab (43.5 percent). The rate of serious adverse events was also lower in vedolizumab-treated patients than adalimumab (11.0% vs. 13.7% respectively).
 
“The VARSITY study addresses critical questions concerning the selection of biologic therapy in ulcerative colitis. The goal of treatment of this disease is to achieve clinical remission and mucosal healing, and these results clearly highlight the benefits seen with vedolizumab versus adalimumab towards these important outcomes.” said Dr. Bruce E. Sands, primary investigator of the VARSITY study and Chief of both the Dr. Henry D. Janowitz Division of
Gastroenterology at Mount Sinai Hospital, and the Icahn School of Medicine at Mount Sinai in New York.
 
Jeff Bornstein, M.D., Executive Medical Director, Takeda added, “The study gives physicians invaluable knowledge towards treatment decisions when starting biologic therapy. This is also the first time we have seen a direct comparison between two medicines with distinct modes of action in ulcerative colitis. This is an exciting time in the landscape of ulcerative colitis treatment, as head-to-head clinical data has not previously been available to guide treatment decisions around biologic therapies.”
 
The VARSITY study comprised a random selection of 769 patients, all of whom had shown an inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or one TNFα-antagonist other than adalimumab before being enrolled. 
 
Patients were randomly placed into one of two treatment groups - vedolizumab IV and placebo SC or adalimumab SC and placebo IV. Patients in the vedolizumab group were administered 300 mg of vedolizumab IV at weeks 0, 2, 6 and every 8 weeks after until week 46, along with placebo SC at week 0 and every 2 weeks until week 50. The adalimumab group were administered 160 mg of adalimumab SC at week 0, 80 mg at week 2 and 40 mg every 2 weeks until week 50, along with placebo IV at weeks 0, 2, 6 and every 8 weeks thereafter until week 46. Dose escalation was not permitted in either treatment arm during the study.1, 



Posted by : GoDubai Editorial Team
Viewed 5246 times
Posted on : Monday, March 11, 2019  
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of GoDubai.com.
Previous Story : A New Manufacturing Approach to Optical Transceivers
Next Story : RAK Hospital wins MRM business award for the 2nd time
Email this article Print this article

Share this article with your friends and followers
NewsVine

Comments

Back to Top  
Most Viewed Press Release posted in the last 7 days
Boss Bottled Oud Aromatic and Saffron: the New Enticing Fragrances
Michael Kors Co-hosts the 10th Anniversary of the Annual Filmmakers Dinner
Police Is the Official Eyewear in the Sony Pictures Film “Men in Blacktm: Intern...
Longchamp & Kendall Jenner Celebrate the Launch of the Longchamp Lgp Collection ...
Travel Essentials Guide
Eberhard & Co. pays extravagant tribute to Alfa Romeo with Quadrifoglio Verde ch...
Crazy Diamonds – Tradition With a Twist
Salvatore Ferragamo Features Leather Sunglasses In the Spring/summer 2019 Adver...
Embrace the Spirit of the Holy Month of Ramadan at Yas Mall, The Mall at World T...
Pure Gold Jewellers launches Arabic calligraphy diamond pendants for Eid
A Contemporary Ode to Ancient Metallurgy
Supreme Armenian Patriarch Hails UAE as Global Model of Peaceful Coexistence
Dubai Customs organizes first of its kind Suhur gathering for government female ...
Western Furniture announces Best Buy sale during Ramadan
Dubai Customs receives WCO executive and showcases best communication practices
Dubai Smart City Accelerator Invites Applications for Third Cohort
Celebrate Father's Day With TUMI
Grandweld Shipyards launches tenth boat of KOC fleet
Pogacar Rides Uae Team Emirates' Wave of Success With Gc Win in California
Dubai Investments supports UAE's Women of Determination through social program
Quran Tech by Dubai Culture inspires visitors at The Dubai Mall in a hi-tech way
Game Of Phones: 8 reasons why software should sit on the throne
Um Al Quwain Police and Pure Gold Jewellers unite prisoners with their families ...
Dubai Cares successfully wraps up its Ramadan volunteering initiative with the p...
SLC launches ‘Tolerance-related Legislation' awareness initiative to position th...
Dubai Culture gathers the community to support ‘Well of Hope'
Dubai Municipality down Public Prosecution to retain NAS Wheelchair Basketball title
Celebrate Eid Al-fitr With Limitless Beach Views at Le Meridien Al Aqah
New Discovery Sport: Enhanced for Every Family Adventure
Germany the next step for Nissan e.dams' Formula E Challenge
W Motors Joins Partner Iconiq Motors at World Intelligence Congress in Tianjin, China
HP and Siemens Deepen Additive Manufacturing Alliance to Advance Digital Manufac...
Ministry of Community Development, Etihad Airways And Abu Dhabi Airports Provide...
EEG Environemtnal Drawing Competition 2019
National Geographic Abu Dhabi Announces Sharjah Reserves Documentary Series in p...
The All-new Flying Spur: the Luxury Grand Touring Sedan
Dry Hair: Causes & How to Combat It
Saudi's KAUST first Middle East university to chair Europe's supercomputing ISC 2020
Ramadan & Eid celebrations across Abu Dhabi & Al Ain Malls
"The Family's Happiness and Stability"
Turkish Airlines to Open Five Lounges at the New Istanbul Airport
The American Community School of Abu Dhabi Awards the Haitham Zamzam Al Hammadi Medal
Saif Al Kaabi wins men's open race in NAS Cycling Challenge, 12-year-old Issa ba...
Nissan to equip new Skyline with world's first next-gen driver assistance system
61 percent of employees believe sustainability is mandatory for modern businesse...
This Ramadan, experience IKEA at Al-Futtaim Toyota
Up Your Haircare Routine with This Protein-Rich Range for Ultimate Hydration
Dubai Islamic Affairs and Charitable Activities Department honours sponsors and ...
Bawabat Al Sharq Mall takes visitors back in time with Ramadan Zaman
Jafza to Infuse Aed 1.3 Billion Into Dubai's Economy